Compulsive buying and spending occupies a clinically important but diagnostically unresolved position in contemporary psychiatry. Its clinical reality — the functional impairment, the characteristic phenomenology, the psychological mechanisms — is well enough established to justify clinical attention and intervention. Its diagnostic status, neurobiological basis, and optimal nosological classification remain genuinely uncertain, and that uncertainty should be communicated honestly to patients, policymakers, and colleagues rather than obscured by confident theoretical claims that exceed the evidence.
Biologically, the evidence points toward involvement of reward and inhibitory control systems shared with other behavioral addictions and impulse-control disorders, but the neurobiological literature is insufficiently developed to establish specific pathophysiology, identify diagnostic biomarkers, or definitively resolve the addiction-versus-impulse-control question. The wanting-liking dissociation model provides useful mechanistic framing consistent with available behavioral evidence, as does the negative urgency construct from the impulsivity literature. Neither has been operationalized into clinically validated assessment or treatment tools for this condition.
Psychologically, the mood-regulatory function of compulsive buying is the best-documented and most clinically actionable finding. The behavior is maintained primarily by its reliable reduction of negative affect, and treatment approaches that address this function — developing alternative affect-regulatory strategies alongside reducing buying behavior — are more likely to produce durable change than approaches targeting only behavioral topography. The identity and self-esteem functions are less extensively documented but clinically ubiquitous and must be addressed in individual formulations, particularly where buying is primarily serving self-concept maintenance.
Socially and environmentally, the structural conditions that enable and amplify compulsive buying — consumer credit, e-commerce architecture, marketing psychology, BNPL infrastructure — are both clinically relevant and, at the individual level, modifiable. Environmental modification targeting these structural enablers is a first-line clinical intervention that does not depend on resolving theoretical debates about nosological status. Clinicians who attend only to psychological dimensions without engaging with the financial and environmental architecture sustaining the behavior will produce incomplete treatment plans.
The path toward diagnostic formalization requires validated assessment instruments aligned to explicit diagnostic criteria, adequately powered treatment trials, and sufficient nosological consensus to support a classification decision. Each of these developments is in progress but none is complete. The clinician’s task in the interim is to bring to patients presenting with genuine functional impairment the most rigorous, individualized, and honest formulation that the current state of knowledge permits — acknowledging diagnostic uncertainty without using it as a reason for therapeutic inaction, and treating a behavioral pattern that causes real harm with the clinical seriousness it deserves.